Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · WisdomTree

WisdomTree BioRevolution Fund (WDNA)

Ticker WDNA · Since 2021-06-03 · · Holdings as of Jun 30, 2026

Expense ratio
0.45%$45/yr per $10k
1-yr return
+22.9%as of Dec 2025
Net assets
$2.7Mall share classes
Holdings
81

Bottom line

Is WDNA a good fund? The bottom line

WDNA is an actively managed large blend ETF from WisdomTree.

It charges 0.45% — about $45 a year on every $10,000 invested, cheaper than 81% of large blend funds we track.

It returned +22.9% over one year (as of Dec 31, 2025, per its prospectus).

With $2.7 million in net assets and 81 holdings, its largest position is Twist Bioscience Corp (5.9%) and the top 10 make up 30.7% of the portfolio.

What stands out

  • Low cost: cheaper than 81% of large blend peers

What to watch

  • Small fund ($2.7 million) — small funds are likelier to close

Updated Nov 19, 2026

What WDNA invests in

The WisdomTree BioRevolution Fund (the Fund) seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (the Index).

The Fund employs a passive management or indexing investment approach designed to track the performance of the Index. The Fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the Index whose risk, return, and other characteristics resemble the risk, return, and other characteristics of the Index as a whole. The Fund invests, under normal circumstances, at least 80% of its net assets, plus any borrowings for investment purposes, in constituents of the Index and/or investments that have economic characteristics that are substantially similar to the economic characteristics of such constituents. WisdomTree, Inc. (WisdomTree), the index provider (the Index Provider) and parent company of the Funds investment adviser, WisdomTree Asset Management, Inc. (WisdomTree Asset Management or the…

From the fund's prospectus (filed Oct 28, 2026).

WDNA performance

Fund calendar-year total returns, 2022–2025 2022: −26.1%; 2023: −2.3%; 2024: −14.1%; 2025: +22.9% −26.1% 2022 −2.3% 2023 −14.1% 2024 +22.9% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
WDNA+22.9%——
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full WDNA performance history →

What WDNA costs

On a $10,000 investment, WDNA's 0.45% expense ratio costs about $45 a year. The prospectus estimates $567 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full WDNA fee table →

WDNA top 10 holdings

#Holding% of fund
1Twist Bioscience Corp TWST5.95%
2Moderna Inc MRNA4.14%
3Eli Lilly & Company LLY4.08%
4Johnson & Johnson JNJ2.97%
5United Therapeutics Corp UTHR2.45%
6Natera Inc NTRA2.32%
7Tempus Ai Inc TEM2.28%
8Immunome Inc IMNM2.26%
9Structure Therapeutics Inc GPCR2.11%
10Stoke Therapeutics Inc STOK2.09%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 30.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to WDNA

More funds like WDNA →

WDNA FAQ

What is the expense ratio of WDNA?
WDNA's expense ratio is 0.45%, which works out to about $45 a year for every $10,000 invested. The prospectus estimates total costs of $567 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is WDNA a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 81% of large blend peers; small fund ($2.7 million) — small funds are likelier to close. This is general information, not personalized advice.
What does WDNA hold?
WDNA's largest holdings are Twist Bioscience Corp (5.9%), Moderna Inc (4.1%), Eli Lilly & Company (4.1%), Johnson & Johnson (3.0%), United Therapeutics Corp (2.4%). It holds 81 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages WDNA?
WDNA is offered by WisdomTree through WisdomTree Trust.